ArticleMicrobial cell factories2026
Acetate as alternative carbon source for production of mono- and di-rhamnolipids in Pseudomonas putida KT2440.
Article in Microbial cell factories, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe bacterium Pseudomonas putida KT2440 is used as a safe platform for rhamnolipid production via expression of the rhlABC genes, yielding mono- and di-rhamnolipid congeners. While glucose is commonly used as a carbon source, more sustainable alternatives such as acetate from waste streams or electrolysis are gaining interest. These two carbon sources are assimilated into the core carbon metabolism through distinct entry points. The impact of this on the proteome and rhamnolipid congener composition remain unclear. In this study, P. putida JAG1 was used to compare rhamnolipid production and composition during growth on glucose and acetate. Additionally, the impact of formate as a non-assimilable electron donor and the potential of modeled electrochemically derived CO₂-based carbon mixtures were evaluated.
resultsRhamnolipid precursor synthesis involves the rhamnose pathway and de-novo fatty acid synthesis. While glucose feeds directly into the rhamnose pathway and acetate into fatty acid synthesis, both carbon sources resulted in a similar di-rhamnolipid fraction of approximately 75 mol%. Although the carbon source significantly influenced the proteome profile, the carbon-to-nitrogen consumption ratio remained constant (C/N ≈ 15). Proteomic differences in P. putida JAG1 comparing the two carbon sources suggest ATP independent acetyl-CoA recycling as energy saving strategy. Enzyme abundances moreover suggest a coupling of the glyoxylate shunt and glycerol metabolism as strategy for gluconeogenesis. Growth rates, as well as biomass and product yields, were slightly lower on acetate compared to glucose. Co-feeding formate with acetate did not cause significant changes relative to acetate alone. Simultaneous consumption of acetate, formate, and ethanol only slightly affect product-per-biomass yields but strongly shifted the composition toward mono-rhamnolipids. Furthermore, comparison of the di-rhamnolipid producer with a mono-rhamnolipid producer indicates that di-rhamnolipid formation is associated with a higher molar product yield.
conclusionsAcetate resembles a viable alternative carbon source for rhamnolipid production with only slight drawbacks to glucose. The metabolism of the microbial cell factory P. putida JAG1 appears homeostatic in presence of a single assimilable carbon source without affecting the rhamnolipid congener composition. The availability of a second assimilable carbon source, however, shifted the composition in favor of the mono-rhamnolipid. The molar product yield per carbon atom was higher during production of di-rhamnolipids compared to sole production of mono-rhamnolipids, highlighting it as a promising target product for future studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.